



**Supplemental Figures.**

**Supplemental Figure 1.**




**Supplemental Figure 1.** Polymorphonuclear cell (PMN) viability following irradiation. PMN were irradiated at 7500 cGy. Trypan blue was used to assess cell viability over time.

## Supplemental Figure 2.



**Supplemental Figure 2.** Gating strategy used to determine PR1-CTL frequency. Cells were stained with CD3, CD4, CD8 and PR1/HLA-A2-dextramer and the lineage (lin) markers CD14, CD16 and CD19. The percentage of PR1/HLA-A2 dextramer<sup>+</sup> cells were determined from live, Lin<sup>-</sup>, CD3<sup>+</sup>, CD4<sup>-</sup>, CD8<sup>+</sup> cells.

**Supplemental Figure 3**



**Supplemental Figure 3.** Melanoma cross-presents NE and P3. Melanoma 526 HLA-A2+ cells were cultured with soluble NE or P3 (10  $\mu\text{g}/\text{mL}$ ) at increasing time-points and then analyzed for expression of (A) PR1/HLA-A2 or (B) HLA-A2. Mean $\pm$ SEM of median fluorescence intensity (MFI) from duplicate wells stained for (A) PR1/HLA-A2 or (B) HLA-A2 is shown from a representative experiment. ANOVA followed by Tukey test was performed using Prism 5.0 software (\*\* $P < 0.01$ ).